Biotech Values

[DewDiligence]

Re: GTCB:

>> The Laureate Pharma agreement seems to fly in the face of their restructuring announcement of Feb 24th …Does this mean no new proteins and completing only present deals like Centracor? I'm a little lost here on their true business plan.<<

I believe GTCB’s greatest underlying value is as a contract manufacturer for both finished drugs and intermediates. HSA, which has utility in many drug formulations, fits nicely in the second category.

ATryn could be a modest-selling drug in its own right, but it is probably more consequential as a “proof of concept” that a transgenically-produced protein can obtain regulatory approval in a major jurisdiction.

The malaria program is mostly for public relations, IMHO, and won’t produce substantial profits.

>> I take it from the GTCB Yahoo board your pretty much in agreement with Norman Klien's assessment of Atryn approval path in Europe? <<

I’m not sure which of Norman’s comments you are commenting on, but I’m assuming that the CPMP and EMEA will use all of their allotted time to review ATryn.